Hedy Kindler to Angiogenesis Inhibitors
This is a "connection" page, showing publications Hedy Kindler has written about Angiogenesis Inhibitors.
Connection Strength
0.634
-
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 2011 Mar; 12(3):256-62.
Score: 0.313
-
Antiangiogenic therapies for mesothelioma. Hematol Oncol Clin North Am. 2005 Dec; 19(6):1137-45, viii.
Score: 0.218
-
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022 02; 126(2):265-274.
Score: 0.041
-
Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance). Angiogenesis. 2022 02; 25(1):47-55.
Score: 0.040
-
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging. 2004 Jul; 20(1):122-8.
Score: 0.012
-
New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol. 2002 Feb; 29(1):82-96.
Score: 0.010